推薦產品
形狀
solid
SMILES 字串
Cl.Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1
InChI
1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H
InChI 密鑰
KPMKNHGAPDCYLP-UHFFFAOYSA-N
應用
Nimustine hydrochloride is an antineoplastic.
訊號詞
Danger
危險聲明
防範說明
危險分類
Acute Tox. 3 Oral
儲存類別代碼
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Nancy Berte et al.
Molecular cancer therapeutics, 15(11), 2665-2678 (2016-11-04)
Malignant gliomas exhibit a high level of intrinsic and acquired drug resistance and have a dismal prognosis. First- and second-line therapeutics for glioblastomas are alkylating agents, including the chloroethylating nitrosoureas (CNU) lomustine, nimustine, fotemustine, and carmustine. These agents target the
Marina Pajic et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(22), 7020-7033 (2017-08-20)
Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.Experimental Design: We studied responses to various mono- and bifunctional alkylating agents in a genetically engineered mouse model for BRCA1/p53-mutant breast cancer.
A Shiraishi et al.
Carcinogenesis, 21(10), 1879-1883 (2000-10-07)
O(6)-methylguanine-DNA methyltransferase plays vital roles in preventing induction of mutations and cancer as well as cell death related to alkylating agents. Mice defective in the MGMT: gene, encoding the methyltransferase, were used to evaluate cell death-inducing and tumorigenic activities of
Bastiaan Evers et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(1), 99-108 (2009-12-17)
Hereditary breast cancer is partly explained by germline mutations in BRCA1 and BRCA2. Although patients carry heterozygous mutations, their tumors have typically lost the remaining wild-type allele. Selectively targeting BRCA deficiency may therefore constitute an important therapeutic approach. Clinical trials
Hajime Asada et al.
The Journal of veterinary medical science, 77(6), 677-684 (2015-02-27)
Canine histiocytic sarcoma (HS) is an aggressive tumor type originating from histiocytic cell lineages. This disease is characterized by poor response to chemotherapy and short survival time. Therefore, it is of critical importance to identify and develop effective antitumor drugs
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務